Abstract
X-linked inhibitor of apoptosis (XIAP) deficiency is a rare primary immunodeficiency and gastrointestinal (GI) lesions in XIAP deficiency are similar to Crohn’s disease. For patients with Crohn’s disease, endoscopic balloon dilation (EBD) is known to be a standard procedure for intestinal strictures including upper GI tract. However, there are no articles which mention the efficacy of EBDs for the strictures in upper GI tract in patients with XIAP deficiency. Herein, we describe an 18-year-old male with XIAP deficiency in whom EBDs for the rectum, ileocecal valve (ICV), and duodenum were performed. Before hematopoietic stem cell transplantation (HSCT), GI endoscopy revealed strictures of the rectum, ICV and duodenum with active ulcers. Although these ulcers healed after HSCT, the strictures progressed. Therefore, we performed EBDs for the strictures of the rectum, ICV, and duodenum. In contrast studies, we did not find any other strictures in the small intestine. Throughout the patient’s clinical course, no complications of EBD occurred. He started eating after EBDs, but abdominal symptoms did not relapse without any dietary restrictions. Our case suggests that EBD could be an effective and safe procedure for intestinal strictures including upper GI tract after HSCT in patients with XIAP deficiency.
X-linked inhibitor of apoptosis (XIAP) deficiency is a rare primary immunodeficiency, and the incidence of mutations in XIAP is estimated to be 1–2 cases per million live births [1]. The main clinical manifestations are hemophagocytic lymphohistiocytosis, splenomegaly, and gastrointestinal (GI) lesions. The clinical and histological features of GI lesions in patients with XIAP deficiency are similar to those in patients with Crohn’s disease (CD) [2]. It was demonstrated that 4% of male patients with pediatric-onset CD had private variants in XIAP [3]. GI lesions in XIAP deficiency are generally severe and drug-resistant, and the only curative treatment is hematopoietic stem cell transplantation (HSCT) [4].
It is possible that patients with XIAP deficiency may develop intestinal strictures like those with CD [5]. In patients with CD, endoscopic balloon dilation (EBD) is known to be a standard procedure for intestinal strictures [6]. We reported another case of a patient with XIAP deficiency who underwent EBDs after HSCT for a stricture of the ileocecal valve (ICV) [7]. However, there are no articles which mention the safety and efficacy of EBDs for the intestinal strictures including upper GI tract in patients with XIAP deficiency. Herein, we describe a case of XIAP deficiency in whom EBDs for multiple strictures of rectum, ICV and duodenum were performed after HSCT.
The study’s protocol was waived by the Institutional Review Board of Hokkaido University Hospital. Written informed consent was obtained.
An 18-year-old boy with XIAP deficiency was referred to our hospital for HSCT. He was diagnosed as having CD when he was 11 years of age in another hospital. He had been treated with various treatments such as steroids, azathioprine, infliximab, adalimumab, or ustekinumab. Nevertheless, clinical remission had never been achieved. Moreover, he repeatedly developed hemophagocytic lymphohistiocytosis. Therefore, genetic analysis was performed, and it revealed XIAP deficiency.
Before HSCT, colonoscopy revealed multiple active ulcers in the large intestine (Fig. 1A and B), a mild stricture of the rectum (Fig. 2A) and a severe stricture of the ICV (Fig. 3A) with active ulcers. Moreover, esophagogastroduodenoscopy revealed a mild stricture in the duodenum with an active ulcer (Fig. 4A). Due to these strictures and multiple ulcers, he could only consume a concentrated liquid diet. After HSCT, the strictures of the rectum (Fig. 2B) and duodenum (Fig. 4B) progressed, and the nasal endoscope could not be advanced through these strictures. Since the active ulcers were healing, we decided to perform EBDs. We first dilated the stricture of the rectum using a through-the-scope balloon up to 12 mm (Fig. 2C and D), and the scope could be advanced. The multiple ulcers in the large intestine were healing (Fig. 1C and D), and the stricture of the ICV remained severe (Fig. 3B). Next, we dilated the stricture of the ICV up to 10 mm (Fig. 3C and D), and the scope could be advanced. Finally, we performed EBD for the stricture of the duodenum up to 10 mm (Fig. 4C and D). Throughout the patient’s clinical course, no EBD complications occurred. In contrast studies, we did not find any other strictures in the small intestine (Fig. 5). He started eating after the EBDs, but abdominal symptoms did not relapse without any dietary restrictions. We have been following him for 4 months and the GI patency is maintained without any symptoms.
XIAP deficiency is mostly a pediatric, drug-resistant disease, and its symptoms are generally severe. The only curative treatment for XIAP deficiency is HSCT, and a previous study revealed the efficacy of HSCT for GI lesions [8]. In the present case, the patient had been treated with various treatments for CD, but no drugs were remarkably effective for his GI lesions. However, mucosal healing was achieved after HSCT, as previously reported.
Little has been reported about HSCT being associated with a risk of proceeding GI strictures in patients with XIAP deficiency. In cases of CD, it was reported that rapid mucosal healing by anti-tumor necrosis factor-α antibodies may result in excess scar tissue formation and strictures [9]. GI lesions in XIAP deficiency are similar to those in CD [2]. Thus, in the present case, it was possible for the fibrotic strictures to progress during the process of subsiding inflammation, as in CD.
There is no standard procedure for treating strictures in XIAP deficiency; therefore, we referred to the strategy used for treating strictures in patients with CD because of the similarity between XIAP deficiency and CD. Previous studies reported that performing EBD for intestinal strictures in patients with CD is safe and effective to avoid surgery [6]. There are some criteria regarding EBDs for CD: (1) a short stricture (< 4 cm) with minimal inflammation, (2) lack of malignancy or high-grade dysplasia, (3) lack of a fistula orifice close to the stricture or an abscess in the stricture area, and (4) straight strictures in line with the bowel lumen [10]. Previous studies reported that main complications of EBD for CD are acute bleeding and perforations, and a larger balloon size may be associated with a higher complication rate [11]. In the present case, the strictures met the criteria of EBD for CD; therefore, we chose this procedure as treatment. Our patient’s strictures were very severe, so we dilated the strictures with a small balloon size (10–12 mm) to minimize the risk of complications. Consequently, no complications of EBD occurred, and clinical remission was achieved without any dietary restrictions or surgery.
Little is known about the effects of EBD for strictures of upper GI tract in patients with CD; however, in a meta-analysis, Bettenworth et al. [12] suggested that EBD for CD-associated strictures of the upper GI tract to be a valuable alternative to surgery, with a high rate of short-term technical and clinical success, moderate long-term efficacy, and an acceptable rate of complications. Like CD patients, our case suggests that EBD could be an effective and safe procedure for strictures of upper GI tract in patients with XIAP deficiency.
In conclusion, EBD could be an effective and safe procedure for intestinal strictures including upper GI tract after HSCT in patients with XIAP deficiency. XIAP deficiency patients with intestinal strictures after HSCT could avoid surgery, if EBD is properly performed.
Notes
Funding Source
The authors received no financial support for the research, authorship, and/or publication of this article.
Author Contribution
Conceptualization, data curation, formal analysis, methodology: Otagiri S. Project administration: Otagiri S, Katsurada T, Sakamoto N. Resources: Otagiri S, Katsurada T, Sakurai K, Sugita J. Supervision: Katsurada T, Sakamoto N. Visualization: Otagiri S, Sakurai K, Sugita J. Writing - original draft: Otagiri S. Writing - review & editing: all authors. Approval of final manuscript: all authors.
REFERENCES
2. Aguilar C, Lenoir C, Lambert N, et al. Characterization of Crohn disease in X-linked inhibitor of apoptosis-deficient male patients and female symptomatic carriers. J Allergy Clin Immunol. 2014; 134:1131–1141.
3. Zeissig Y, Petersen BS, Milutinovic S, et al. XIAP variants in male Crohn’s disease. Gut. 2015; 64:66–76.
4. Ono S, Okano T, Hoshino A, et al. Hematopoietic stem cell transplantation for XIAP deficiency in Japan. J Clin Immunol. 2017; 37:85–91.
5. Sunseri WM, Kugathasan S, Keljo DJ, et al. IBD LIVE case series: case 3: very early-onset inflammatory bowel disease: when genetic testing proves beneficial. Inflamm Bowel Dis. 2015; 21:2958–2968.
6. Atreja A, Aggarwal A, Dwivedi S, et al. Safety and efficacy of endoscopic dilation for primary and anastomotic Crohn’s disease strictures. J Crohns Colitis. 2014; 8:392–400.
7. Otagiri S, Sugiura R, Katsurada T, et al. Gastrointestinal: endoscopic balloon dilations for an intestinal stricture in a patient with X-linked inhibitor of apoptosis deficiency. J Gastroenterol Hepatol. 2019; 34:1895.
8. Tsuma Y, Imamura T, Ichise E, et al. Successful treatment of idiopathic colitis related to XIAP deficiency with allo-HSCT using reduced-intensity conditioning. Pediatr Transplant. 2015; 19:E25–E28.
9. Chang CW, Wong JM, Tung CC, Shih IL, Wang HY, Wei SC. Intestinal stricture in Crohn’s disease. Intest Res. 2015; 13:19–26.
10. Klag T, Wehkamp J, Goetz M. Endoscopic balloon dilation for Crohn’s disease-associated strictures. Clin Endosc. 2017; 50:429–436.